Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus CEFOTAN.
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs CEFOTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, and activating autolytic enzymes.
1-2 g IV every 8-12 hours; maximum 12 g/day
1-2 g IV/IM every 12 hours for 5-10 days; up to 6 g/day for severe infections.
None Documented
None Documented
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Terminal elimination half-life: 4.5 hours (intravenous). In patients with renal impairment (CrCl <30 mL/min), half-life extends to approximately 20–30 hours, requiring dose adjustment.
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Primarily renal (unchanged); ~88% excreted in urine within 24 hours. Biliary/fecal elimination is negligible (<1% as metabolites).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic